利福喷丁剂量治疗药物敏感结核:无缝2/3期随机临床试验第一阶段
该研究为无缝2/3期随机对照试验第一阶段,在中国16个中心纳入400例药物敏感肺结核成人,比较含利福喷丁10、15或20 mg/kg的4个月方案与标准6个月方案。主要终点为第8周前因安全原因永久停药率,20 mg/kg组停药率较高(14.6%),15和20 mg/kg组培养转阴率较高。
要点
- 利福喷丁15和20 mg/kg组第8周前培养转阴率高于10 mg/kg组和对照组。
- 20 mg/kg组因安全原因永久停药率最高(14.6%),需加强安全监测。
- 各方案治疗结束良好结局率相似,15 mg/kg组数值略高但置信区间重叠。
核心结论
- 利福喷丁15和20 mg/kg可提高第8周前培养转阴率,但20 mg/kg组安全相关停药更频繁,需谨慎评估获益风险并加强监测。
研究设计与样本
- 无缝2/3期随机对照试验第一阶段,2023年2月1日至2024年9月29日在中国16个中心纳入400例药物敏感肺结核成人,随机1:1:1:1分组。
主要发现
- 主要终点(第8周前因安全原因永久停药)发生率:利福喷丁10 mg/kg组9.3%(9/97)、15 mg/kg组8.9%(9/101)、20 mg/kg组14.6%(14/96)、对照组3.0%(3/99)。
- 第8周前培养转阴率:10 mg/kg组73.8%(45/61)、15 mg/kg组84.8%(56/66)、20 mg/kg组87.9%(51/58)、对照组78.0%(46/59)。
- 治疗结束良好结局率:对照组81.4%(79/97),10 mg/kg组80.9%(RR 0.99,95%CI 0.87-1.14),15 mg/kg组87.1%(RR 1.07,95%CI 0.95-1.21),20 mg/kg组82.6%(RR 1.01,95%CI 0.89-1.16)。
关键数值与推荐
- 利福喷丁10、15、20 mg/kg每日联合异烟肼、莫西沙星和吡嗪酰胺的4个月方案,对照为异烟肼、利福平、吡嗪酰胺和乙胺丁醇的标准6个月方案。
临床怎么用
- 利福喷丁15或20 mg/kg可考虑用于提高早期培养转阴,但20 mg/kg需加强安全监测和获益风险评估。
局限性
- 本文为第一阶段结果,样本量400例,长期疗效和复发数据未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the safety and efficacy across rifapentine doses ranging from 10 to 20 mg/kg for pulmonary drug-susceptible tuberculosis population. METHODS: The stage 1 of this seamless phase 2/3 randomized controlled trial recruited enrolled adults with drug-susceptible tuberculosis at 16 sites in China between 1 February 2023 and 29 September 2024 (NCT05401071). Participants were randomly divided (1:1:1:1) to receive one of three 4-month regimens containing rifapentine 10, 15, or 20 mg/kg daily plus isoniazid, moxifloxacin, and pyrazinamide, or a standard 6-month regimen consisting of isoniazid, rifampicin, pyrazinamide, and ethambutol. In the stage 1, the primary endpoint was the incidence of permanent regimen discontinuation for safety reasons by week 8. Key secondary endpoints included culture conversion before week 8, adverse events during treatment, and favourable outcomes at the end of treatment. RESULTS: A total of 400 participants underwent randomization in stage 1. The incidences of primary endpoint were 9.3% (9/97), 8.9% (9/101), and 14.6% (14/96) in the rifapentine 10, 15, and 20 mg/kg groups, and 3.0% (3/99) in the control group, respectively. Culture conversion before week 8 occurred in 73.8% (45/61), 84.8% (56/66), and 87.9% (51/58) of participants in the rifapentine 10, 15, and 20 mg/kg groups, and 78.0% (46/59) in the control group. Favourable outcomes at the end of treatment were similar across the groups: 81.4% (79/97) in the control group, 80.9% in the rifapentine 10 mg/kg group (relative risk [RR], 0.99; 95% CI, 0.87-1.14), 87.1% in the rifapentine 15 mg/kg group (RR, 1.07; 95% CI, 0.95-1.21), and 82.6% in the rifapentine 20 mg/kg group (RR, 1.01; 95% CI, 0.89-1.16). CONCLUSIONS: Both rifapentine 15 and 20 mg/kg yielded higher culture conversion rates. However, safety-related discontinuation, particularly in the 20 mg/kg group, was more frequent, highlighting the need for careful benefit-risk assessment and enhanced safety monitoring.
引用
- Li Y, Song L, Feng Z, et al. Rifapentine dosing for drug-susceptible tuberculosis: stage 1 of a seamless phase 2/3 randomized clinical trial. Clin Microbiol Infect. 2026. PMID: 41974353. doi:10.1016/j.cmi.2026.04.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。